Private equity firm KKR has acquired Medicover, the Swedish-headquartered international healthcare and diagnostic services provider, in a deal valued at an undisclosed amount. The transaction takes the Nasdaq Stockholm-listed company private, ending its public listing following a period of sustained growth across its European and Asian operations.
Medicover, founded in 1995 in response to rising demand for private healthcare in Poland, operates in 19 countries and employs more than 48,000 people. Its largest markets include Poland, Germany, Romania, India, and Ukraine. The company runs two core divisions: Healthcare Services, which covers outpatient clinics, hospitals, fertility treatment, dental care, and wellness offerings such as sports packages and diets, and Diagnostic Services, which provides a broad range of clinical laboratory tests from routine screening to advanced monitoring.
For KKR, the acquisition aligns with its long-standing focus on healthcare infrastructure and services. The firm has previously invested in medical diagnostics and hospital networks across Europe, and Medicover’s integrated model of preventive care and laboratory testing offers a stable, recurring revenue base. The deal also provides KKR with a platform to expand Medicover’s footprint in high-growth markets, particularly in India and Eastern Europe, where demand for private healthcare is rising.
The acquisition is expected to accelerate Medicover’s capital investment plans, which were previously constrained by quarterly reporting and public market scrutiny. As a private entity, the company can pursue longer-term projects, including new clinic openings and laboratory automation, without the pressure of short-term earnings targets. KKR’s operational expertise in scaling healthcare businesses is likely to support these efforts.
The combined entity will continue to operate under the Medicover brand, with existing management expected to remain in place. The transition to private ownership is anticipated to close after regulatory approvals, after which Medicover will delist from Nasdaq Stockholm. For patients and clients, the change in ownership is not expected to alter service delivery, while the company’s expansion plans may gain momentum under KKR’s backing.